SavedAdd your journal

Journals / Black Sea Journal of Health Science / 2026 / Cilt: 9 Sayı: 5

Metabolic Syndrome Effects over Heart Tissue: A Histomorphological Glance under the Light of p97/VCP and SVIP

Şeyma Kipel(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-4176-5136
Ayça Bilginoğlu Topcu(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-1657-2607
Makbule Fulya Tutar Selçuk(Avcılar Murat Kölük Devlet Hastanesi)0000-0002-8961-9883
Hilal Nakkaş(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-0901-8875
Pages
176–185
Publication Date
2026-09-15
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, MetS induces significant histomorphological and molecular alterations in cardiac tissue.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Metabolic syndrome(MetS) is a cluster of metabolic disorders that significantly increases the risk of heart disease and type 2 diabetes. p97/VCP (Valosin-Containing Protein), is an ATPase enzyme that regulates many vital processes in the cell such as cell cycle control, apoptosis, protein degradation, and cellular stress.
📊
Key Findings & Data:It affects processes such as cellular stress response, protein accumulation, and degradation, particularly through its interaction with the p97/VCP protein.
💡
Conclusion & Impact:In conclusion, MetS induces significant histomorphological and molecular alterations in cardiac tissue.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Heart · Metabolic syndrome · p97/VCP

Abstract

Metabolic syndrome(MetS) is a cluster of metabolic disorders that significantly increases the risk of heart disease and type 2 diabetes. p97/VCP (Valosin-Containing Protein), is an ATPase enzyme that regulates many vital processes in the cell such as cell cycle control, apoptosis, protein degradation, and cellular stress. Small VCP-interacting protein (SVIP) has various important functions in the cell which are particularly in the endoplasmic reticulum and proteasome systems. SVIP is a small but effective regulator of the protein recycling and quality control system in the cell. It affects processes such as cellular stress response, protein accumulation, and degradation, particularly through its interaction with the p97/VCP protein. MetS is one of the most important risk factors for cardiovascular diseases. However, the roles of p97/VCP and SVIP in cardiac tissue affected by MetS remain unclear. Therefore, this study aimed to investigate the histomorphological changes and the expression levels of p97/VCP and SVIP in rat heart tissue in a MetS model. The histomorphological alterations in heart tissues were evaluated using Hematoxylin-Eosin and Weigert Van Gieson staining methods. Using the immunohistochemical technique, the expression of p97/VCP and SVIP in rat heart tissue were examined. Statistical analyses were conducted and p<0.05 was considered statistically significant. Histological examination revealed morphological alterations in the MetS group (n=8) compared to the control group (n=8).Immunohistochemical findings demonstrated that p97/VCP expression significantly decreased, whereas SVIP expression significantly increased in the MetS group compared with the control group (P<0.05). In conclusion, MetS induces significant histomorphological and molecular alterations in cardiac tissue. The altered expression patterns of p97/VCP and SVIP may contribute to the pathogenesis of MetS-related cardiovascular complications. These findings may provide insight into the molecular mechanisms underlying cardiac damage associated with metabolic syndrome.

Özet

Metabolic syndrome(MetS) is a cluster of metabolic disorders that significantly increases the risk of heart disease and type 2 diabetes. p97/VCP (Valosin-Containing Protein), is an ATPase enzyme that regulates many vital processes in the cell such as cell cycle control, apoptosis, protein degradation, and cellular stress. Small VCP-interacting protein (SVIP) has various important functions in the cell which are particularly in the endoplasmic reticulum and proteasome systems. SVIP is a small but effective regulator of the protein recycling and quality control system in the cell. It affects processes such as cellular stress response, protein accumulation, and degradation, particularly through its interaction with the p97/VCP protein. MetS is one of the most important risk factors for cardiovascular diseases. However, the roles of p97/VCP and SVIP in cardiac tissue affected by MetS remain unclear. Therefore, this study aimed to investigate the histomorphological changes and the expression levels of p97/VCP and SVIP in rat heart tissue in a MetS model. The histomorphological alterations in heart tissues were evaluated using Hematoxylin-Eosin and Weigert Van Gieson staining methods. Using the immunohistochemical technique, the expression of p97/VCP and SVIP in rat heart tissue were examined. Statistical analyses were conducted and p<0.05 was considered statistically significant. Histological examination revealed morphological alterations in the MetS group (n=8) compared to the control group (n=8).Immunohistochemical findings demonstrated that p97/VCP expression significantly decreased, whereas SVIP expression significantly increased in the MetS group compared with the control group (P<0.05). In conclusion, MetS induces significant histomorphological and molecular alterations in cardiac tissue. The altered expression patterns of p97/VCP and SVIP may contribute to the pathogenesis of MetS-related cardiovascular complications. These findings may provide insight into the molecular mechanisms underlying cardiac damage associated with metabolic syndrome.

🔖

Cite This Article

Kipel, Ş., Topcu, A. B., Selçuk, M. F. T., Nakkaş, H. (2026). Metabolic Syndrome Effects over Heart Tissue: A Histomorphological Glance under the Light of p97/VCP and SVIP. Black Sea Journal of Health Science, Cilt: 9 Sayı: 5, 176–185. https://doi.org/10.19127/bshealthscience.1914438

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (24)

  1. Abella, V., Scotece, M., Conde, J., Lopez, V., Lazzora, V., Pino, J., Reino, J., Gualillo, O. (2014). Adipokines, metabolic syndrome and rheumatic diseases. Journal of Immunology Research, 1–14. https://doi.org/10.1155/2014/343746
  2. Anthony, S. R., Guarnieri, A. R., Gozdiff, A., Helsy, A., Qwens, A., Tranter, M. (2019). Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis. Clinical Science, 133(22), 2329–2344. https://doi.org/10.1042/CS20190578
  3. Bilginoglu, A., Selcuk, M. F. T., Nakkas, H., Turan, B. (2018). Pioglitazone provides beneficial effect in metabolic syndrome rats via affecting intracellular Na+ dyshomeostasis. Journal of Bioenergetics and Biomembranes, 50(6), 437–445. https://doi.org/10.1007/s10863-018-9776-6
  4. Cavelera, M., Wang, J., Frangogiannis, N. G. (2014). Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Translational Research, 164(4), 323–335. https://doi.org/10.1016/j.trsl.2014.05.001
  5. Cayli, S., Alimogullari, E., Piskin, I., Bilginoglu, A. (2021). Effect of pioglitazone on the expression of ubiquitin proteasome system and autophagic proteins in rat pancreas with metabolic syndrome. Journal of Molecular Histology, 52(5), 929–942. https://doi.org/10.1007/s10735-021-10013-1
  6. Ferrari, V., Cristofani, R., Tedesco, B., Crippa, V., Chierichetti, M., Casarotto, E., Cozzi, M., Mina, F., Piccolella, M., Galbiati, M., Rusmini, P., Poletti, A. (2022). Valosin containing protein (VCP): A multistep regulator of autophagy. International Journal of Molecular Sciences, 23(4). https://doi.org/10.3390/ijms23041939
  7. Ilhan, R., Üner, G., Yilmaz, S., Sahar, E., Cayli, A., Erzurumlu, Y., Gözen, O., Kirmizibayrak, P. (2022). Novel regulation mechanism of adrenal cortisol and DHEA biosynthesis via the endogenous ERAD inhibitor small VCP-interacting protein. Scientific Reports, 12(1), 869. https://doi.org/10.1038/s41598-022-04821-y
  8. Kartal, B., Alimoğulları, E., Çaylı, S. (2023). The immunoexpression of valosin‐containing protein and small VCP‐interacting protein in rat ovaries. Anatomia Histologia Embryologia, 52(4), 546–551. https://doi.org/10.1111/ahe.12914
  9. Lizano, P., Rashed, E., Kang, H., Dai, H., Sui, X., Yan, L., Qiu, H., Depre, C. (2013). The valosin-containing protein promotes cardiac survival through the inducible isoform of nitric oxide synthase. Cardiovascular Research, 99(4), 685–693. https://doi.org/10.1093/cvr/cvt136
  10. Lizano, P., Rashed, E., Stoll, S., Zhou, N., Wen, H., Hays, T., Qin, G., Xie, L., Depre, C., Qiu, H. (2017). The valosin-containing protein is a novel mediator of mitochondrial respiration and cell survival in the heart in vivo. Scientific Reports, 7(1). https://doi.org/10.1038/srep46324
  11. Lloyd-Jones, D. M. (2016). Slowing progress in cardiovascular mortality rates. JAMA Cardiology, 1(5), 599. https://doi.org/10.1001/jamacardio.2016.1348
  12. MacRae, C. A., Roden, D. M., Loscalzo, J. (2016). The future of cardiovascular therapeutics. Circulation, 133(25), 2610–2617. https://doi.org/10.1161/CIRCULATIONAHA.116.023555
  13. Müller, J., Deinhardt, K., Rosewell, I., Warren, G., Shima, D. (2007). Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochemical and Biophysical Research Communications, 354(2), 459–465. https://doi.org/10.1016/j.bbrc.2006.12.206
  14. Ozsoy, A. Z., Cayli, S., Sahin, C., Ocaklı, S., Sancı, T., İlhan, D. (2018). Altered expression of p97/valosin containing protein and impaired autophagy in preeclamptic human placenta. Placenta, 67, 45–53. https://doi.org/10.1016/j.placenta.2018.05.013
  15. Rakhe, N., Bhatt, L. K. (2024). Valosin-containing protein: A potential therapeutic target for cardiovascular diseases. Ageing Research Reviews, 101, 102511. https://doi.org/10.1016/j.arr.2024.102511
  16. Ren, S., Xu, X. (2015). Role of autophagy in metabolic syndrome-associated heart disease. Molecular Basis of Disease, 1852(2), 225–231. https://doi.org/10.1016/j.bbadis.2014.04.029
  17. Shu, H., Peng, Y., Hang, W., Zhou, N., Wang, D. (2021). Emerging role of VCP/p97 in cardiovascular diseases: Novel insights and therapeutic opportunities. Biochemical Society Transactions, 49(1), 485–494. https://doi.org/10.1042/BST20200981
  18. Sidiropoulos, P., Karvounaris, S., Boumpas, D. T. (2008). Metabolic syndrome in rheumatic diseases: Epidemiology, pathophysiology, and clinical implications. Arthritis Research & Therapy, 10(3), 207. https://doi.org/10.1186/ar2397
  19. Stoll, S., Xi, J., Ma, B., Leimena, C., Behringer, E., Qin, G., Qiu, H. (2019). The valosin- containing protein protects the heart against pathological Ca2+ overload by modulating Ca2+ uptake proteins. Toxicological Sciences, 171(2), 473–484. https://doi.org/10.1093/toxsci/kfz164
  20. Sun, X., Zhou, N., Ma, B., Wu, W., Stoll, S., Lai, L., Qin, G., Qiu, H. (2021). Functional inhibition of valosin-containing protein induces cardiac dilation and dysfunction in a new dominant-negative transgenic mouse model. Cells, 10(11), 2891. https://doi.org/10.3390/cells10112891
  21. van Den Boom, J., Meyer, H. (2017). VCP/p97-mediated unfolding as a principle in protein homeostasis and signaling. Molecular Cell, 69(2), 182–194. https://doi.org/10.1016/j.molcel.2017.10.028
  22. Yu, G., Bai, Y., Zhang, Z. (2024). Valosin-containing protein (VCP)/p97 oligomerization. Subcellular Biochemistry, 485–501. https://doi.org/10.1007/978-3-031-58843-3_18
  23. Zhou, N., Ma, B., Stoll, S., Hays, T., Qiu, H. (2017). The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload. Aging Cell, 16(5), 1168–1179. https://doi.org/10.1111/acel.12653
  24. Zhou, N., Chen, X., Xi, J., Ma, B., Leimena, C., Stoll, S., Qin, G., Wang, C., Qiu, H. (2020). Genomic characterization reveals novel mechanisms underlying the valosin-containing protein-mediated cardiac protection against heart failure. Redox Biology, 36, 101662. https://doi.org/10.1016/j.redox.2020.101662